Efficacy of ensitrelvir for cough due to COVID-19 Omicron variant in medical healthcare workers.

IF 4.1 2区医学 Q2 MICROBIOLOGY

Antimicrobial Agents and Chemotherapy Pub Date : 2024-10-08 Epub Date: 2024-08-29 DOI:10.1128/aac.01064-24

Naoyuki Miyashita, Yasushi Nakamori, Makoto Ogata, Naoki Fukuda, Akihisa Yamura, Tomoki Ito

引用次数: 0

Abstract

We evaluated the efficacy of ensitrelvir for the treatment of cough due to coronavirus disease 2019 Omicron variant in medical healthcare workers. A total of 633 patients were registered in this study: 206 patients chose ensitrelvir and 427 patients chose symptomatic treatment. Difference in score changes using the Leicester Cough Questionnaire between groups was 3.17 on day 4, 3.24 on day 7, and 2.46 on day 14. The analysis demonstrated a significant difference at all time points.

查看原文本刊更多论文

ensitrelvir对医护人员因COVID-19 Omicron变异体引起的咳嗽的疗效。

我们评估了ensitrelvir治疗医护人员因冠状病毒病2019 Omicron变种引起的咳嗽的疗效。这项研究共登记了 633 名患者：206 名患者选择了安斯瑞韦，427 名患者选择了对症治疗。两组患者在莱斯特咳嗽问卷中的得分变化差异为：第4天3.17分，第7天3.24分，第14天2.46分。分析表明在所有时间点上都存在显著差异。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Antimicrobial Agents and Chemotherapy 医学-微生物学

CiteScore

10.00

自引率

8.20%

发文量

762

审稿时长

3 months

期刊介绍： Antimicrobial Agents and Chemotherapy (AAC) features interdisciplinary studies that build our understanding of the underlying mechanisms and therapeutic applications of antimicrobial and antiparasitic agents and chemotherapy.